Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Azilsartan in Essential Hypertension
NCT00759551Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of azilsartan in essential hypertension (7 arms), sponsored by Takeda. Primary endpoint: Change from Baseline in sitting clinic diastolic blood pressure at 8 weeks. Started Aug 2004; status: completed.
02
Drugs
azilsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00759551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759551.